Streetbeat News

CGON

Cg Oncology Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

33.05

Mkt cap

2.3B

Volume

67K

High

34.10

P/E Ratio

-2.12

52-wk high

50.23

Low

32.55

Div yield

N/A

52-wk low

25.77

Shares of Science Applications International Corporation (NASDAQ:SAIC) fell 11% following a 9% year-over-year revenue decline in Q1 2025, despite slightly beating revenue estimates and meeting EPS expectations. Other notable stock movements include Microbot Medical Inc. (NASDAQ:MBOT) jumping 92.5% after FDA approval for a clinical trial, and Bio-Path Holdings, Inc. (NASDAQ:BPTH) rising 75% following positive interim results from a Phase 2 study.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 5:56 pm

U.S. stocks were mixed on Monday, with the Dow Jones index falling around 100 points. Several stocks saw significant gains, including Stericycle, Inc. (NASDAQ:SRCL) which rose 15% after announcing a $7.2 billion acquisition deal with Waste Management Inc. (NYSE:WM). GameStop Corp. (NYSE:GME) shares jumped 34.5% following a Reddit post by Roaring Kitty. MarineMax, Inc. (NYSE:HZO) surged 27% amid acquisition talks with OneWater Marine Inc. Other notable gainers included Liquidia Corporation (NASDAQ:LQDA), Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 2:39 pm

HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology (NASDAQ:CGON) and maintained a price target of $75.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:25 am

CG Oncology will present the final results from its Phase 2 CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab for BCG-unresponsive high-risk NMIBC at the ASCO 2024 Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 12:08 pm

CG Oncology (NASDAQ:CGON) received mixed analyst ratings with an updated average 12-month price target of $64.7, marking a significant increase from the previous $43.00. The company, a late-stage biopharmaceutical focused on bladder cancer therapies, shows substantial revenue growth but faces challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 5:00 pm

Goldman Sachs analyst Corinne Johnson upgraded CG Oncology (NASDAQ:CGON) from Neutral to Buy and increased the price target from $43 to $50.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:41 pm

Goldman Sachs analyst Corinne Johnson upgrades CG Oncology (NASDAQ:CGON) from Neutral to Buy and sets a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:25 pm

HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology (NASDAQ:CGON) and maintained a $75 price target.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:28 pm

CG Oncology (NASDAQ:CGON) reported a significant improvement in its Q1 earnings, with losses narrowing to $(0.36) per share from $(3.22) per share YoY, marking an 88.82% increase in performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 1:03 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on CG Oncology (NASDAQ:CGON) and maintained a $75 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 1:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.